Vaxxinity, Inc. (VAXX): Price and Financial Metrics
GET POWR RATINGS... FREE!
VAXX POWR Grades
- Sentiment is the dimension where VAXX ranks best; there it ranks ahead of 97.26% of US stocks.
- The strongest trend for VAXX is in Momentum, which has been heading down over the past 177 days.
- VAXX ranks lowest in Momentum; there it ranks in the 1st percentile.
VAXX Stock Summary
- VAXX's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.47 -- higher than just 4.24% of US-listed equities with positive expected earnings growth.
- VAXX's went public 1.21 years ago, making it older than just 0.53% of listed US stocks we're tracking.
- As for revenue growth, note that VAXX's revenue has grown -101.52% over the past 12 months; that beats the revenue growth of just 0.55% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to VAXXINITY INC, a group of peers worth examining would be ADMP, OCFT, FEMY, SNGX, and PALT.
- To dig deeper into the stock's financial statements, go to VAXX's page on browse-edgar?action=getcompany&CIK=0001851657.
VAXX Valuation Summary
- VAXX's EV/EBIT ratio is -3.6; this is 136.36% lower than that of the median Healthcare stock.
- VAXX's EV/EBIT ratio has moved up 47.4 over the prior 14 months.
Below are key valuation metrics over time for VAXX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| VAXX | 2023-01-20 | -378200 | 4.7 | -3.7 | -3.6 |
| VAXX | 2023-01-19 | -315100 | 3.9 | -3.1 | -3.0 |
| VAXX | 2023-01-18 | -298800 | 3.7 | -2.9 | -2.8 |
| VAXX | 2023-01-17 | -293700 | 3.7 | -2.9 | -2.8 |
| VAXX | 2023-01-13 | -254600 | 3.2 | -2.5 | -2.4 |
| VAXX | 2023-01-12 | -253400 | 3.2 | -2.5 | -2.4 |
VAXX Stock Price Chart Interactive Chart >
VAXX Price/Volume Stats
| Current price | $4.00 | 52-week high | $8.35 |
| Prev. close | $3.84 | 52-week low | $1.24 |
| Day low | $3.65 | Volume | 621,915 |
| Day high | $4.17 | Avg. volume | 584,809 |
| 50-day MA | $2.06 | Dividend yield | N/A |
| 200-day MA | $2.43 | Market Cap | 504.22M |
Vaxxinity, Inc. (VAXX) Company Bio
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as dementia with Lewy Body and multiple system atrophy; and an anti-tau product candidate for various neurodegenerative conditions, including AD It is also developing UB-313 that targets Calcitonin Gene-Related Peptide to fight migraines; and Anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events, as well as UB-612/UB-612A for Covid-19 prevention. The company has a collaboration with United Biomedical, Inc. for the development of UB-612 in Taiwan. Vaxxinity, Inc. was founded in 2014 and is based in Dallas, Texas.
Latest VAXX News From Around the Web
Below are the latest news stories about VAXXINITY INC that investors may wish to consider to help them evaluate VAXX as an investment opportunity.
Why Shares of Vaxxinity Jumped This WeekInvestors are hoping the company's COVID-19 vaccine will turn the company from a clinical-stage biotech to a commercial one. |
Vaxxinity to Present at the 2023 J.P. Morgan Healthcare ConferenceDALLAS, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present an update on the Company and its pipeline at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 3 p.m. ET. A live webcast of the presentation will be available under “Events & Presentations” in the Investor section of the |
Estimating The Fair Value Of Vaxxinity, Inc. (NASDAQ:VAXX)Today we will run through one way of estimating the intrinsic value of Vaxxinity, Inc. ( NASDAQ:VAXX ) by projecting... |
Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612Vaxxinity’s next-generation COVID-19 booster candidate UB-612 achieves primary and key secondary immunogenicity endpoints in a pivotal head-to-head heterologous booster trial against three authorized vaccine platforms: mRNA (Pfizer-BioNTech’s BNT162b2), adenovirus vector (AstraZeneca’s ChAdOx1-S), and inactivated virus (Sinopharm’s BIBP) UB-612 elicits superior neutralizing antibody titers and seroconversion rates against both Wuhan and Omicron BA.5 variants compared to adenovirus vector (ChAdOx |
Why Shares of Vaxxinity Soared This WeekPositive news regarding a different company's Alzheimer's treatment may have helped Vaxxinity. |
VAXX Price Returns
| 1-mo | 185.71% |
| 3-mo | 205.34% |
| 6-mo | 64.61% |
| 1-year | -33.11% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 185.71% |
| 2022 | -75.04% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...